Sector News

Boehringer appoints first CEO from founding family in 25 years

November 9, 2015
Life sciences

(Reuters) – Germany’s No. 2 drugmaker, Boehringer Ingelheim, on Friday appointed as chief executive Hubertus von Baumbach, a great-grandson of founder Albert Boehringer, putting a member of the family at the helm for the first time in 25 years.

Von Baumbach, 48, is currently Boehringer’s finance chief and will replace CEO Andreas Barner, 62, when he retires on June 30, 2016, the unlisted family-owned group said in a statement.

“Hubertus von Baumbach knows the corporation and its various divisions and his time on the Board of Managing Directors has prepared him well for the company’s future challenges,” shareholders’ committee chairman Christian Boehringer said.

“Along with colleagues on the Board of Managing Directors, he will continue the drive for change at Boehringer Ingelheim in order to secure the company’s independence in the long term,” he added.

After his retirement, Barner will join the shareholders’ committee, which is comparable to a corporate supervisory board. (Reporting by Patricia Weiss and Maria Sheahan; editing by Jason Neely)

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach